
|Videos|January 29, 2018
A Dose-Escalation Study of Regorafenib in mCRC
Tanios Bekaii-Saab, MD, professor of medicine, Mayo Clinic, discusses a randomized phase II trial to evaluate dosing strategies for regorafenib (Stivarga) in patients with refractory metastatic colorectal cancer.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves Iberdomide, the First CELMoD for Relapsed/Refractory Multiple Myeloma
2
How the Immune System Drives Nerve Growth in TNBC
3
AMH Testing Predicts Chemotherapy Benefit in RxPONDER Breast Cancer
4
FAQ: When and How to Discontinue Lenalidomide Maintenance in Multiple Myeloma
5



































